Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

The Anticipated Clinical Effect of the new Alzheimer Drug ANAVEX PLUS

in a Predictive Humanised Cortical Cognitive Model for Alzheimer’s Disease
ANAVEX PLUS, the proprietary combination of ANAVEX 2-73 (AV2-73) with donepezil, the most prescribed Alzheimer’s drug, combines cholinergic pharmacology with muscarinic and sigma-1 receptor activity and can potentially combine symptomatic, neuroprotective and potentially disease-modifying properties, as illustrated in a paper by C. Missling of Anavex Life Sciences, T. Maurice of INSERM U710, University of Montpellier 2, France, A. Spiros of In Silico Biosciences, Lexington, MA, P. Roberts of OHSU, Portland, OR, and H. Geerts of University of Pennsylvania, PA. 
https://international-pharma.com/wp-content/uploads/2014/03/the-anticipated…pdf.pdf

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025